• TECHNOLOGY
    • Peripheral Solutions
      • Impede
      • Impede-FX
      • Impede-FX RAPIDFILL
      • Trellix
    • Neurovascular Solutions
      • Trellix
    • Aortic Solutions
  • EVIDENCE
  • COMPANY
    • About the Company
    • Distributors
    • Careers
    • Compliance
    • Patents
  • NEWS & EVENTS
CONTACT
Shape Memory Medical Shape Memory Medical
  • TECHNOLOGY
    • Technology
      • Peripheral Solutions
        • Impede
        • Impede-FX
        • Impede-FX RAPIDFILL
        • Trellix
      • Neurovascular Solutions
        • Trellix
      • Aortic Solutions
  • EVIDENCE
    • Publications
    • Presentations & Webinars
    • Clinical Trials
    • Case Studies
  • Company
    • COMPANY
      • Distributors
      • Careers
      • Compliance
      • Patents
  • News & Events
CONTACT
Shape Memory Medical

Shape Memory Medical Announces European Enrollment in the AAA-SHAPE Randomized Controlled Pivotal Trial

By shapememory inPress Releases

February 20, 2025 08:00 AM Eastern Daylight Time

SAN JOSE, Calif.–(BUSINESS WIRE)–

Shape Memory Medical Inc., developer of custom shape memory polymers for endovascular markets, announced the first enrollment in Europe in the AAA-SHAPE Pivotal Trial, the Company’s prospective, multicenter, randomized, open-label trial to determine safety and effectiveness of the IMPEDE-FX RapidFill® Device to improve abdominal aortic aneurysm (AAA) sac behavior when used with elective endovascular aneurysm repair (EVAR). The patient was treated by Dr. Jan Heyligers, MD, PhD, consultant vascular surgeon, and Professor Dr. Patrick Vriens, MD, PhD, vascular surgeon, at Elisabeth TweeSteden Hospital in Tilburg, the Netherlands.

“We congratulate Dr. Heyligers, Professor Vriens, and the clinical study team at Elisabeth TweeSteden Hospital for being the first center in Europe to enroll in the AAA-SHAPE Pivotal Trial,” said Dr. Marc Schermerhorn, AAA-SHAPE National Principal Investigator and Chief of Vascular Surgery at Beth Israel Deaconess Medical Center in Boston, MA. “This milestone reflects the unwavering dedication of the physician investigators to advance embolization solutions and enhance patient care worldwide.”

AAA-SHAPE – Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion – will enroll 180 patients with infrarenal abdominal aortic aneurysms (AAA) across up to 50 sites in the U.S., Europe, and New Zealand. Key endpoints will compare sac diameter and volume change, endoleak rates, and secondary interventions.

“We are proud to be the first site in Europe to treat a patient in this groundbreaking trial,” said Dr. Heyligers. “Research shows that 60% of aneurysms either fail to regress or expand within a year after EVAR, often leading to rehospitalizations, additional interventions, and higher mortality rates. The results of this study will be essential in determining whether the IMPEDE-FX RapidFill, with its unique properties, can significantly enhance post-EVAR AAA outcomes and elevate the standard of patient care,” continued Heyligers.

IMPEDE-FX RapidFill, the investigational device, incorporates Shape Memory Medical’s novel shape memory polymer, a proprietary, porous, radiolucent, embolic scaffold that is crimped for catheter delivery and self-expands upon contact with blood. In AAA-SHAPE, IMPEDE-FX RapidFill is intended to fill the aneurysm blood lumen around a commercially available EVAR stent graft to promote aneurysm thrombosis and sac shrinkage.

The AAA-SHAPE Pivotal trial builds upon the AAA-SHAPE early feasibility study which enrolled 35 patients in New Zealand and the Netherlands to assess the use of IMPEDE-FX RapidFill for abdominal aortic aneurysm (AAA) sac embolization during EVAR. Investigators like Dr. Heyligers who participated in the early feasibility study play an important role in applying initial key learnings of this application to this next phase of the AAA-SHAPE program.

About Shape Memory Medical

Shape Memory Medical is a California-based, global medical device company focused on innovative therapeutic solutions using shape memory polymer technology. With commercialized devices in embolization space, the company is actively leveraging its platform technology to develop novel applications for the management of complex aortic pathologies.

In countries recognizing CE marking, the IMPEDE and IMPEDE-FX Embolization Plugs and the IMPEDE-FX RapidFill are indicated to obstruct or reduce the rate of blood flow in the peripheral vasculature. The IMPEDE and IMPEDE-FX Embolization Plugs are PMDA approved in Japan. In the United States, the IMPEDE Embolization Plug is indicated to obstruct or reduce the rate of blood flow in the peripheral vasculature, and the IMPEDE-FX Embolization Plug is indicated for use with the IMPEDE Embolization Plug to obstruct or reduce the rate of blood flow in the peripheral vasculature. In the United States, IMPEDE-FX RapidFill is an investigational device, limited by Federal (or United States) law to investigational use. For more information, visit www.shapemem.com.

 

Contacts

Maryanne Koller
m.koller@shapemem.com
408-649-5175

 

296
Like this post
  • Shape Memory Medical Announces First Patient Treated in the AAA-SHAPE Randomized Controlled Pivotal Trial
    Previous PostShape Memory Medical Announces First Patient Treated in the AAA-SHAPE Randomized Controlled Pivotal Trial
  • Next PostShape Memory Medical’s President and CEO to present at LSI USA
    Shape Memory Medical Announces First Patient Treated in the AAA-SHAPE Randomized Controlled Pivotal Trial

Related Posts

Shape Memory Medical’s President and CEO to present at LSI USA
Press Releases

Shape Memory Medical’s President and CEO to present at LSI USA

Shape Memory Medical Announces First Patient Treated in the AAA-SHAPE Randomized Controlled Pivotal Trial
Press Releases

Shape Memory Medical Announces First Patient Treated in the AAA-SHAPE Randomized Controlled Pivotal Trial

Prospective Study Shares Early Clinical Experience with Shape Memory Polymer Vascular Plugs for Pelvic Venous Disease
Press Releases

Prospective Study Shares Early Clinical Experience with Shape Memory Polymer Vascular Plugs for Pelvic Venous Disease

Shape Memory Medical Completes $38 Million in Financing to Advance Endovascular Embolization
Press Releases

Shape Memory Medical Completes $38 Million in Financing to Advance Endovascular Embolization

Shape Memory Medical logo white
Follow us

Careers
Complaints
Compliance
Distributors
Patents
Patient Information
Portal
Privacy

Address
1321 Ridder Park Drive, Suite 10
San Jose, CA 95131

Telephone & Contact
+1 408 649 5175
info@shapemem.com

©2024 Shape Memory Medical
All Rights Reserved
LIT1099 Rev H

Copy
Cookies To make this site work properly, we sometimes place small data files called cookies on your device. To continue using this web site, click the Accept button or the Change Settings button for more options.
Accept
Change Settings
Cookie Box Settings
Cookie Box Settings

Privacy settings

Decide which cookies you want to allow. You can change these settings at any time. However, this can result in some functions no longer being available. For information on deleting the cookies, please consult your browser’s help function. Learn more about the cookies we use.

With the slider, you can enable or disable different types of cookies:

  • Block all
  • Essential
  • Functionality
  • Analytics
  • Advertising

This website will:

This website won't:

This website will:

  • Essential: Remember your cookie permission setting
  • Essential: Allow session cookies
  • Essential: Gather information you input into a contact forms, newsletter and other forms across all pages

This website won't:

  • Remember your login details
  • Functionality: Remember social media settings
  • Functionality: Remember selected region and country
  • Analytics: Keep track of your visited pages and interaction taken
  • Analytics: Keep track about your location and region based on your IP number
  • Analytics: Keep track of the time spent on each page
  • Analytics: Increase the data quality of the statistics functions
  • Advertising: Tailor information and advertising to your interests based on e.g. the content you have visited before. (Currently we do not use targeting or targeting cookies.
  • Advertising: Gather personally identifiable information such as name and location

This website will:

  • Essential: Remember your cookie permission setting
  • Essential: Allow session cookies
  • Essential: Gather information you input into a contact forms, newsletter and other forms across all pages
  • Essential: Keep track of what you input in a shopping cart
  • Essential: Authenticate that you are logged into your user account
  • Essential: Remember language version you selected
  • Functionality: Remember social media settings
  • Functionality: Remember selected region and country

This website won't:

  • Remember your login details
  • Analytics: Keep track of your visited pages and interaction taken
  • Analytics: Keep track about your location and region based on your IP number
  • Analytics: Keep track of the time spent on each page
  • Analytics: Increase the data quality of the statistics functions
  • Advertising: Tailor information and advertising to your interests based on e.g. the content you have visited before. (Currently we do not use targeting or targeting cookies.
  • Advertising: Gather personally identifiable information such as name and location

This website will:

  • Essential: Remember your cookie permission setting
  • Essential: Allow session cookies
  • Essential: Gather information you input into a contact forms, newsletter and other forms across all pages
  • Essential: Keep track of what you input in a shopping cart
  • Essential: Authenticate that you are logged into your user account
  • Essential: Remember language version you selected
  • Functionality: Remember social media settings
  • Functionality: Remember selected region and country
  • Analytics: Keep track of your visited pages and interaction taken
  • Analytics: Keep track about your location and region based on your IP number
  • Analytics: Keep track of the time spent on each page
  • Analytics: Increase the data quality of the statistics functions

This website won't:

  • Remember your login details
  • Advertising: Use information for tailored advertising with third parties
  • Advertising: Allow you to connect to social sites
  • Advertising: Identify device you are using
  • Advertising: Gather personally identifiable information such as name and location

This website will:

  • Essential: Remember your cookie permission setting
  • Essential: Allow session cookies
  • Essential: Gather information you input into a contact forms, newsletter and other forms across all pages
  • Essential: Keep track of what you input in a shopping cart
  • Essential: Authenticate that you are logged into your user account
  • Essential: Remember language version you selected
  • Functionality: Remember social media settings
  • Functionality: Remember selected region and country
  • Analytics: Keep track of your visited pages and interaction taken
  • Analytics: Keep track about your location and region based on your IP number
  • Analytics: Keep track of the time spent on each page
  • Analytics: Increase the data quality of the statistics functions
  • Advertising: Use information for tailored advertising with third parties
  • Advertising: Allow you to connect to social sitesl Advertising: Identify device you are using
  • Advertising: Gather personally identifiable information such as name and location

This website won't:

  • Remember your login details
Save & Close